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cells can be targeted
bymetabolic inhibitors
to treat MPNs.
Increased energy requirement and metabolic reprogramming are hallmarks of cancer cells.
We show that metabolic alterations in hematopoietic cells are fundamental to the path-
ogenesis of mutant JAK2–driven myeloproliferative neoplasms (MPNs). We found that
expression of mutant JAK2 augmented and subverted metabolic activity of MPN cells,
resulting in systemic metabolic changes in vivo, including hypoglycemia, adipose tissue
atrophy, and early mortality. Hypoglycemia in MPN mouse models correlated with hy-
peractive erythropoiesis andwas due to a combination of elevated glycolysis and increased
oxidative phosphorylation. Modulating nutrient supply through high-fat diet improved
survival, whereas high-glucose diet augmented the MPN phenotype. Transcriptomic and
metabolomic analyses identified numerousmetabolic nodes in JAK2-mutant hematopoietic
stem and progenitor cells that were altered in comparison with wild-type controls. We
studied the consequences of elevated levels of Pfkfb3, a key regulatory enzyme of gly-
colysis, and found that pharmacological inhibition of Pfkfb3 with the small molecule 3PO
reversed hypoglycemia and reduced hematopoietic manifestations ofMPNs. These effects
were additive with the JAK1/2 inhibitor ruxolitinib in vivo and in vitro. Inhibition of gly-
colysis by 3PO altered the redox homeostasis, leading to accumulation of reactive oxygen species and augmented
apoptosis rate. Our findings reveal the contribution of metabolic alterations to the pathogenesis of MPNs and suggest
that metabolic dependencies of mutant cells represent vulnerabilities that can be targeted for treating MPNs. (Blood.
2019;134(21):1832-1846)
Introduction
Myeloproliferative neoplasms (MPNs) are clonal disorders of
hematopoietic stem cells driven by gain-of-function mutations
in JAK2, MPL, or CALR genes.1-7 Additional mutations that
modify the course of disease have also been described.8
Three phenotypic manifestations of MPNs can be distinguished:
polycythemia vera (PV), essential thrombocythemia (ET), and
primary myelofibrosis.9
Genetic and epigenetic changes associated with cancers are
often coupled with reprogramming of cellular metabolism, a
paradigm that has been recognized as 1 of the hallmarks of
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Figure 1. Hematopoietic-specific expression of mutant JAK2–induced adipose tissue atrophy, severe hypoglycemia, and global metabolic changes in MPN mice. (A)
Representative pictures of wild-type (WT) and VF- and E12-mutant mice at 2 to 4 months after induction with tamoxifen. Red and blue asterisks indicate reduced subcutaneous
and epididymal white adipose tissue (eWAT), respectively. (B) Body weight at 2 to 4months after induction with tamoxifen (n5 8-12mice per genotype). (C) eWATweight (n5 8-
12 mice per genotype). (D) Ratios of lean body mass/total body mass (solid colors) and fat mass/total body mass (transparent colors) at 2 to 4 months after induction with
tamoxifen (n 5 4-5 mice per group). (E-F) Food intake (E) and locomotor activity (on x-, y-, and z-axes) (F) as measured by comprehensive laboratory animal monitoring system
(n5 5 mice per genotype). (G) Nonfasting blood glucose levels at 12 (VF) and 6 weeks (E12) after tamoxifen induction (n5 5-6 mice per genotype). (H) Serum insulin levels at 12 (VF)
and 6weeks (E12) after tamoxifen induction (n5 5-6 and n5 8mice per genotype, respectively). (I,J) Nonfasting blood glucose levels (I) and time course of change in bodyweight
(J) after tamoxifen induction (n5 5 mice per genotype). (K) Glucose tolerance test (GTT) 6 hours after starvation at 12 (VF) and 6 weeks (E12) after tamoxifen induction (n5 10-12
mice per genotype). (L) Tamoxifen-inducedmice were treated with ruxolitinib (90 mg/kg twice daily). Time course of fasting blood glucose levels, peripheral hemoglobin levels,
and reticulocyte counts (n5 5-6mice per genotype). (M) GTT in recipients transplantedwith BM cells (23 106) fromWT, VF, or E12 donormice (n5 6mice per genotype). All data
are presented as mean 6 standard error of the mean. One- or 2-way analyses of variance followed by Tukey’s multiple comparison tests were used for multiple-group
comparisons. *P , .05, **P , .01, ***P , .001.
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Figure 2. Mutant JAK2–inducedMPNs were vulnerable to modulation of nutrients in vivo. (A) Mice were induced by tamoxifen and treated with normal diet (ND) or HGD
for 7 weeks. Time course of nonfasting blood glucose levels (n5 5-6 mice per treatment and genotype). (B) Peripheral blood counts of HGD- and ND-treatedmice (n5 5-6 mice
per genotype). (C) Spleen weight after 7 weeks of ND or HGD (n5 5-6 mice per treatment and genotype). (D) Nonfasting blood glucose levels in mice exposed to fed-fasting
cycles or continuously fed with ND (n5 4-5 mice per genotype and condition). (E) Peripheral blood counts of mice exposed to fed-fasting cycles or continuously fed with ND. (F)
Spleen weight in mice exposed to fed-fasting cycles or ND (n5 4-5 mice per genotype and condition). (G) Correlation of nonfasting blood glucose levels with peripheral blood
counts. Peripheral blood counts and nonfasting blood glucose levels were monitored 6 to 8 weeks after tamoxifen injections (n5 4-5 mice per genotype). (H-I) Glucose uptake
capacity of erythroid cells in spleen monitored by 2-NBDG fluorescence. After 4 hours of starvation, cells from spleen or BM were exposed to 2-NBDG for 30 minutes and
analyzed by flow cytometry. (H) Histograms show 2-NBDG fluorescence in splenic CD711Ter1191 cells, with quantification of the mean fluorescence intensity (MFI) presented as
bar graphs (middle). 2-NBDG MFI in subsets of erythroid cells (I-V) (right). (I) Glucose uptake capacity of erythroid cells in bone marrow (n 5 6 mice per genotype). All data are
presented as mean6 standard error of the mean. One- or 2-way analyses of variance followed by Tukey’s multiple comparison tests were used for multiple-group comparisons.
*P , .05, **P , .01. RBC, red blood cell.
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Figure 3. HFD treatment ameliorated early lethality phenotype of PV-exhibiting mutant JAK2–expressing mice. (A) Pictures of male WT and VF- and E12-mutant mice
exposed to HFD for 24 weeks. Red and blue asterisks mark reduced subcutaneous and epididymal white adipose tissue (eWAT) fat content, respectively. (B) Time course of body
weight gain of HFD-treatedmice (n5 8-12mice per genotype and sex). (C) Plasma leptin concentration in HFD- and normal diet (ND)–treatedmice (n5 5mice per treatment and
genotype). (D) Nonfasting blood glucose levels in HFD- and ND-treated mice (n 5 5 mice per treatment and genotype). (E) Serum insulin levels in ND- and HFD-treated mice
(n 5 4-5 mice per treatment and genotype). (F) Survival of mice receiving ND or HFD (n 5 12 mice per treatment and genotype). (G) Hemoglobin levels and red blood cell
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cancers.10 Transformed cells require increased supply of nutri-
ents to fuel their augmented energy demands and produce
macromolecules needed for unconstrained proliferation and
differentiation capacities.11,12 Cancer cells can also reprogram
metabolism of neighboring nonmalignant cells through inter-
actions with stromal cells and adipocytes by provoking them
to secrete lipids, amino acids, and other soluble factors, which
can directly influence disease progression.13,14 This may lead to
cachexia, a life-threatening pathological condition involving ad-
ipose tissue atrophy and muscle wasting. Indeed, survival of cancer
patients is inversely correlated with severity of cachexia.15,16
Therefore, delineating differences in metabolic activities between
normal and cancer cells is important and may open new thera-
peutic approaches.
We studied conditional transgenic mouse models of MPNs that
can be induced by tamoxifen to express either JAK2 V617F (VF)
17,18 or a JAK2 exon 12 (N542-E543del) mutation (E12) in he-
matopoietic cells.19 We have previously shown that these mouse
models recapitulate the phenotype of MPN patients, including
aberrant production of platelets and erythrocytes and devel-
opment of splenomegaly. These mice also show early mortality
through incompletely understood mechanisms.18,19
Here we show that expression of mutant JAK2 in hematopoietic
cells leads to cell-autonomous metabolic alterations, such as
increase in glycolysis and oxidative phosphorylation, as well as to
systemic changes, including hypoglycemia and adipose atrophy.
We found that these JAK2-dependent metabolic alterations can
be targeted therapeutically in vivo by limiting nutrient supply
and inhibiting rate-limiting steps in glycolysis, with beneficial
effects on MPN manifestation and survival.
Methods
Mice used in this study were kept in accordance with Swiss
federal regulations, and all experiments were approved by the
Cantonal Veterinary Office of Basel-Stadt. The collection of
blood samples and clinical data from MPN patients was ap-
proved by the Ethik Kommission Beider Basel and the ethics
boards of the University of Bonn and RWTH Aachen University
(Aachen, Germany) and the Clinical Center of Serbia, University
of Belgrade (Belgrade, Serbia). Written informed consent was
obtained from all patients in accordance with the Declaration of
Helsinki. The diagnosis of MPNwas established according to the
revised criteria of the World Health Organization.9
Data-sharing statement
For detailed description of methods, see supplement available
with the online version of this article. For original data and re-
agents, please contact radek.skoda@unibas.ch. RNA sequenc-
ing (RNAseq) data are available at theGene ExpressionOmnibus
under accession #GSE 116571.
Results
Adipose tissue atrophy and severe hypoglycemia in
mice expressing VF or JAK2 exon 12 mutations in
hematopoietic cells
SclCreER VF- and SclCreER E12-mutant mice develop MPNs
within 4 to 5 weeks after induction with tamoxifen.18,19 We no-
ticed that these mice also displayed a marked reduction of fat
tissue and significant decrease in body weight not previously
reported (Figure 1A-B). Epididymal white adipose tissue was
dramatically reduced, leading to an increase in lean body mass
(Figure 1C-D), despite increased food intake and a trend toward
reduced physical activity (Figure 1E-F). VF and E12 strains both
displayed hypoglycemia (Figure 1G). Serum insulin levels were
not suppressed, possibly reflecting a hyperactive insulin axis
(Figure 1H). After induction of the mutant JAK2 by tamoxifen,
hypoglycemia manifested earlier in E12 mice than in VF mice
(Figure 1I) and preceded the reduction in body weight (Figure 1J).
Glucose tolerance test showed that exogenous glucose was im-
mediately used in both VF and E12mice (Figure 1K). Ruxolitinib, a
JAK1/2 tyrosine kinase inhibitor, normalized glucose levels in E12
mice, along with a reduction of red cell parameters (Figure 1L).
The metabolic changes were also present in mice transplanted
with VF or E12 BM cells (Figure 1M), indicating that expression of
mutant JAK2 solely in hematopoietic cells was sufficient to transfer
the metabolic alterations.
To determine whether increased supply of glucose can correct
MPN-associated hypoglycemia and influence disease manifesta-
tions, we exposed JAK2-mutant mice and controls to high-glucose
diet (HGD). However, HGD was unable to correct hypoglycemia in
E12mice (Figure 2A), whereas an increase in erythroid parameters
in peripheral blood was noted in VF mice (Figure 2B), and an
increase in spleen weight occurred in E12 mice (Figure 2C).
Thus, HGD did not ameliorate hypoglycemia, but rather fueled
erythrocytosis and splenomegaly.
We next examined whether reducing glucose supply through
intermittent fasting-feeding regimen may alter the disease
course of MPNs. Caloric restriction by intermittent fasting-
feeding regimen was shown to affect hematopoietic stem and
progenitor cell (HSPC) frequencies and their differentiation ca-
pacity in WT mice.20 Fasting-feeding regimen lowered blood
glucose in VF recipients and in WT mice compared with un-
interrupted feeding, but glucose was uniformly very low in E12
mice, irrespective of regimen (Figure 2D). However, E12 mice
exposed to fasting-feeding regimen displayed slightly lower red
cell parameters and neutrophil numbers (Figure 2E) and also
significantly reduced erythroid progenitors in BM, whereas
erythroid progenitors in spleen were increased (supplemental
Figure 1B). Spleen weight was markedly reduced in E12 mice
(Figure 2F). Thus, reducing glucose and energy supply through
intermittent fasting ameliorated MPN phenotype, including
splenomegaly and blood counts, in E12-mutant mice. The less
prominent changes in VF mice were likely due to the slower
Figure 3 (continued) (RBC), platelet, and neutrophil counts in peripheral blood during HFD or ND treatment in indicated mice (n5 6-8 mice per treatment and genotype). (H)
Bar graph indicating spleen weight of HFD- andND-treatedmice (n5 5-6 mice per genotype). (I) Representative images of hematoxylin and eosin staining of eWAT fromND- or
HFD-treated mice. Scale bars, 100 mm. Bar graph represents the median white adipocyte size of HFD-treated mice (n5 5 mice per). All data are presented as mean6 standard
error of the mean. One- or 2-way analyses of variance followed by Tukey’s multiple comparison tests were used for multiple-group comparisons. Significance in survival curves
was estimated with the log-rank test. *P # .05, **P # .01, ***P # .001.
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kinetics of MPN development after tamoxifen compared with
E12 mice.
To assess whether elevated blood counts and increased he-
matopoietic activity correlate with hypoglycemia, we examined
glucose levels in several additional knock-in or transgenic VF
models of MPNs that displayed various degrees of ET or PV
phenotype21-23 and in a transgenic line (Tg6) that constitutively
overexpressed erythropoietin (Epo) and displayed massive
erythrocytosis.24 A strong inverse correlation between blood
glucose concentration and red cell parameters (eg, hemoglobin
[R2 5 0.822]) was noted, whereas no correlation was seen be-
tween glucose andplatelets, neutrophils, ormonocytes (Figure 2G).
Hypoglycemia was present in all VF models with PV phenotype
and also in Tg6mice with erythrocytosis, as previously reported.25
However, hypoglycemia was absent in VF mice with a pure ET
phenotype. These results suggest that increased glucose con-
sumption by hyperactive erythropoiesis could have been re-
sponsible for hypoglycemia in these mouse models.
To further examineglucose usage,we determinedglucose uptake
using the fluorescent tracer 2-NBDG. VF and E12 cells showed
increased glucose uptake compared with WT controls (Figure
2H-I). Interestingly, the intensity of 2-NBDG showed bimodal
peaks, possibly indicating that a subset of VF and E12 cells was
hyperactive in taking up glucose (Figure 2H). Erythroid cells of
E12mice from spleen showed higher uptake than cells from BM.
Uptake of 2-NBDG in subsets of erythroid precursors was highest
in the fractions 2 and 3, correlating with the highest proliferative
activity of these fractions (Figure 2I). Thus, erythroid cells in MPN
mice took up and avidly consumed glucose.
Because MPN mice showed severe loss of adipose deposits
(Figure 1A-C), we tested whether high-fat diet (HFD) may affect
MPN phenotype and survival. Whereas WT mice receiving HFD
(60% fat) gained weight rapidly and after 24 weeks displayed a
massive increase in body fat, E12mice showed little or no weight
gain or increase in body fat (Figure 3A-B). Female VFmice failed
to gain weight, similar to E12 mice, whereas male VF mice
showed a moderate increase in weight. HFD increased leptin
levels compared with normal chow, but the relative increase was
greater in WT mice (Figure 3C). Hypoglycemia in VF and E12
mice was not corrected by HFD, although a trend toward slightly
higher levels was noted (Figure 3D). Insulin levels increased
under HFD in VF despite hypoglycemia, but remained un-
changed in E12 mice (Figure 3E). Remarkably, survival of E12
mice was substantially prolonged by HFD (P, .001) and allowed
us to observe these mice for up to 30 weeks (Figure 3F). There
was only a trend toward better survival in VF mice. HFD treat-
ment has been shown to negatively affect hematopoietic dif-
ferentiation capacity of HSPCs in the BM niche.26 We observed
slightly reduced red cell parameters, but increased spleen size,
in JAK2-mutant mice receiving HFD (Figure 3G-H).
With normal chow, adipocytes from VF and E12 mice showed
significantly reduced size compared with WT (Figure 3I). With
HFD, the size of adipocytes increased in all genotypes, but
adipocytes from VF and E12 mice remained smaller than adi-
pocytes from WT mice (Figure 3G). Fat tissue from VF and E12
mice also displayed elevated messenger RNA expression of
several inflammatory cytokines as well as CD36, a fatty acid
uptake mediator (supplemental Figure 2A). Mutant JAK2 also
altered brown adipose tissue morphology, with increased
numbers of small fat vacuoles. HFD partially normalized these
alterations (supplemental Figure 2B). In line with the elevated
lipolysis, HFD-treated VF and E12 mice displayed reduced ac-
cumulation of lipids in the liver (supplemental Figure 2C), sug-
gesting that these mice were less prone to hepatic steatosis
upon HFD challenge.
Our data suggest that hematopoietic-specific expression of
mutant JAK2 induced hypoglycemia as a result of increased
consumption of glucose by erythroid cells, which was normalized
by ruxolitinib, and that increased energy demand and elevated
inflammatory cytokines led to lipolysis and adipose atrophy,
which was partially corrected by HFD.
Because some of the metabolic alterations, particularly lipolysis,
seemed to be a counter-regulatory adaptation to hypoglycemia
involving nonhematopoietic tissue, we next sought to specify
metabolic requirements unique to JAK2-mutant HSPCs. We
performed RNAseq in megakaryocyte and erythroid progenitors
(MEPs) of JAK2-mutant and WT mice. The numbers of differ-
entially expressed genes in MEPs from BM of VF and E12 mice
compared with WTMEPs and heatmaps are shown in Figure 4A-
B. Ingenuity pathway analysis–based gene ontology enrichment
revealed that most of the significantly up- or downregulated
genes in JAK2-mutant mice were related to metabolism, JAK/
STAT signaling, and inflammatory signaling pathways (supple-
mental Figure 3A). By competitive gene set testing on the
Molecular Signatures Database hallmark gene sets,27 we also
found that oxidative phosphorylation and JAK/STAT signaling
target genes were among the 4 top gene sets (supplemen-
tal Figure 3B). Consistent with the elevated glucose uptake
Figure 4. Transcriptomic and metabolic profiling identified altered metabolic pathways in HSPCs expressing mutant JAK2. (A) Venn diagram shows number of distinct
and overlapping genes expressed between VF and E12mice as comparedwithWT controls (log fold change [FC]. 1.5 and false discovery rate [FDR], 0.05; n5 3 per genotype).
(B) Heatmap showing differentially expressed genes in BM MEPs as determined by messenger RNA (mRNA) sequencing. Data show FC to the mean. (C-E) Heatmap showing
expression of nutrient transporters (C), glycolysis pathway enzymes (D), and regulators of glycolysis pathway genes (E) in BM MEPs as determined by mRNA sequencing. Data
shown are normalized expression levels in VF and E12 vsWT cells (n5 3 per genotype). (F) Metabolic pathway enrichment analysis of significantly upregulatedmetabolites in BM
MEPs from VF and E12 compared with WT mice as determined by MetaboloAnalyst 3.0 (n 5 3 per genotype; FC . 1.5; P , .05). (G) Measurements of glycolytic rates in BM
lineage-negative Sca-11 and cKit1 (LSK) cells and MEPs. Extracellular acidification rate values were normalized to cell numbers. Data are from 3 independent experiments (n5 6
mice per genotype). (H) Measurements of oxygen consumption rate (OCR), indicative of mitochondrial oxidative phosphorylation in BM LSK cells and MEPs. OCR values were
normalized to cell numbers. Data are from 3 independent experiments (n 5 6 mice per genotype). (I) Glucose uptake capacity of LSK cells and MEPs in BM and spleen as
measured by mean fluorescence intensity (MFI) of 2-NBDG fluorescence (n5 6 mice per genotype). (J) Number of mitochondria per cell in BM LSK andMEP cells as determined
by transmission electron microscopy (TEM) (n 5 3 samples per genotype and 60-100 cells per genotype). (K) Mitochondrial DNA copy number in BM long-term hematopoietic
stem cells (LT-HSCs), multipotent progenitors, and MEPs as measured by quantitative polymerase chain reaction (qPCR) (n 5 3 per genotype). (L) Mitochondrial DNA copy
number in peripheral blood of MPN patients as measured by qPCR presented as violin density plots. The horizontal width of the plots shows the density of the data along the
y-axis. All data are presented as mean6 standard error of the mean. One-way analyses of variance followed by Tukey’s multiple comparison tests were used for multiple group
comparisons. See also supplemental Figures 4 and 5. *P, .05, **P, .01, ***P, .001. FCCP, carbonyl cyanide-p-trifluoromethoxyphenylhydrazone; PMF, primary myelofibrosis.
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Role of Pfkfb3 in the regulation of glycolysis
Figure 5. Increased incorporation of glucose carbon through glycolysis and the pentose phosphate pathway in mutant JAK2–expressing HSPCs. (A) Schematic of
glucose labeling and tracing in BM LSK and MEP cells. Fluorescence-activated cell sorted (FACS) LSK cells and MEPs were cultured with [U-13C6] D-glucose for 8 hours and
analyzed by ion chromatography–Fourier transform mass spectrometry (IC-FTMS) to determine the fate of labeled carbon atoms derived from glucose in various downstream
metabolites. (B) Bar graphs depicting the levels (mmoles per gram of protein) of glucose-derived 13C containing isotopologues of metabolites in glycolysis and pentose
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(Figure 2E-F), we observed increased expression of glucose trans-
porters Glut1, Glut3, and Glut10, glutamine transporter Asct2, and
the Slc27a family of fatty acid transporters (Figure 4C). Furthermore,
enzymes involved in regulation of glycolysis (eg, Pkm1 and
Pfkfb3) and their known transcriptional regulators (eg, Hif-1a,
nMyc, Ahr, and Arnt) were also elevated in MEPs from VF and
E12 mice (Figure 4D-E). These data suggest that activation of
mutant JAK2 signaling altered the expression of genes involved
the regulation of metabolic pathways.
Analysis of messenger RNA expression was complemented with
profiling of metabolite in purified BM MEP cells using liquid
chromatography coupled with mass spectrometry. We found al-
tered concentrations of metabolites that were classified into
groups usingmetabolic pathway enrichment analysis (Figure 4F).28
The observed changes in JAK2-mutant MEPs were consistent
with increased activities of glycolysis, pentose phosphate path-
way, and terpenoidbackbones for steroidbiosynthesis (Figure 4F);
the same changes were also observed in LSK cells (supplemental
Figure 4A). Combined analysis of data obtained by RNAseq and
metabolite profiling also showed altered regulation of glycolysis
and pentose phosphate pathway genes as the main alterations in
MEPs from JAK2-mutant mice (supplemental Figure 4B).
To assess glycolytic activity and mitochondrial respiration, we
performed metabolic flux studies. Aerobic glycolysis, indicative
of Warburg effect,11,29 was elevated in LSK and MEP cells from
VF and E12mice (Figure 4G). The same results were obtained in
total spleen cells (supplemental Figure 4C). However, total BM
cells from E12 mice unexpectedly showed slightly reduced rate
of glycolysis compared with WT BM. Mitochondrial respiration
was assessed by determining the OCR as an indicator of oxi-
dative phosphorylation. BM LSK and MEP cells from VF and E12
mice showed an increased respiration rate compared with WT
controls (Figure 4H). Likewise, unfractionated spleen cells from
VF and E12 mice also showed increased basal respiration rate
and higher maximal respiration rate than WT controls (supple-
mental Figure 4D). No differences in OCR between total BM
cells from VF, E12, and WT mice were detected (supplemental
Figure 4D). In line with the increased rate of glycolysis and
oxidative phosphorylation, LSK cells and MEPs from VF and E12
mice showed increased glucose uptake (Figure 4I), similar to
differentiated erythroid cells (Figure 2H-I).
Because mitochondrial respiration was increased, we used
several methods to determine mitochondrial numbers andmass.
Transmission electron microscopy showed that LSK and MEP
cells of VFmice had reduced numbers of mitochondria, whereas
the numbers of mitochondria of E12 mice were increased in
MEPs (Figure 4J). Likewise, quantification of mitochondrial DNA
copy number by quantitative polymerase chain reaction in E12
showed a similar pattern of decrease in long-term hematopoietic
stem cells and increase in MEPs (Figure 4K), whereas in VFmice,
no differences were noted in WT mice. A similar pattern was
observed using the mitochondrial membrane–specific dye
MitoTracker Green (supplemental Figure 4E). These results show
an overall trend toward a decrease in mitochondrial numbers
and mitochondrial mass in cells from JAK2-mutant mice. Thus,
despite reduced mitochondrial mass, HSPCs from JAK2-mutant
mice showed an increased rate of oxidative phosphorylation. We
also found decreased mitochondrial DNA copy numbers in
peripheral blood granulocytes from MPN patients (Figure 4L).
Because hematopoietic cells of JAK2-mutant mice showed el-
evated expression of glucose transporters and increased
glucose uptake, we examined in greater detail the intracellular
fate of glucose by tracking carbon-13 (13C)–labeled D-glucose
([U-13C6] D-glucose; Figure 5A). Purified MEP and LSK cells were
cultured for 8 hours in serum-free medium with [U-13C6]
D-glucose, and total number of metabolites, as well as number of
13C-labeled metabolites, was determined by ion chromatography–
Fourier transform mass spectrometry.30 The glycolytic interme-
diates showed a high percentage 13C labeling in both WT and
JAK2-mutated cells, whereas the absolute number of glycolytic
intermediates was elevated only in cells from JAK2-mutant mice
(Figure 5B), consistent with increased rate of glycolysis. The total
amount of pyruvate in JAK2-mutant cells was higher than that in
WT cells, in good correlation with the increased expression of
pyruvate kinase (Pkm1). However, only 20% to 30% of pyruvate
was labeled with 13C in cells from all genotypes, suggesting that
a major proportion of pyruvate came from nonglucose sources
(eg, amino acid metabolism). Consequently, the percentage of
contribution of the 13C-labeled pyruvate to the TCA cycle was
low (supplemental Figure 5A). Cells expressing mutant JAK2
also showed strong 13C labeling of pentose phosphate pathway
intermediates, leading to increased biosynthesis of purine nu-
cleotides (Figure 5B; supplemental Figure 5B). Consistently,
phosphoribosyl pyrophosphate synthetase 2 (Prps2), the rate-
limiting enzyme for phosphoribosyl pyrophosphate synthesis, was
highly elevated in JAK2-mutant HSPCs (supplemental Figure 5C).
Taken together, these data suggest that expression of mutant
JAK2 in hematopoietic cells reprogrammed metabolism by
upregulating the expression of nutrient transporters and key
regulatory enzymes of glucose metabolism, resulting in increased
glycolysis, mitochondrial respiration, and nucleotide biosynthesis.
Targeting the activity of Pfkfb3, an early
rate-limiting enzyme in glycolysis, reduces growth
of human VF-expressing cell lines
We found that Pfkfb3, 1 of 4 Pfkfb isoforms, was significantly
elevated in mutant HSPCs both at RNA and protein levels
(Figure 5C-D). This enzyme catalyzes the conversion of fructose-
6-phosphate to F2,6BP, which acts as an allosteric activator on
Figure 5 (continued) phosphate pathways. LSK and MEP cells were collected and pooled from 9 to 12 mice of matching genotype as 1 replicate. Data are from 2 independent
experiments. Insert showing the key rate-limiting step in glycolysis in which the activity of Pfkfb enzyme potentiated activity of rate-limiting enzyme phosphofructokinase (Pfk)
through generation of fructose-2,6-biphosphate (F2,6BP) from fructose-6-phosphate (F6P). 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-1 (3PO) is a specific pharmacological
inhibitor of Pfkfb3 isoform. (C) Pfkfb1-4mRNA expression in MEP cells (n5 3 per genotype). (D) Pfkfb3 protein expression in BM LSK and MEP cells as measured by intracellular
FACS (n5 3 per genotype). (E) Graphical representation of increased glycolysis rate-limiting step involving conversion of F6P to F1,6BP and its positive regulator PFKFB3, which
can be inhibited by 3PO. All data are presented as mean 6 standard error of the mean. See also supplemental Figure 6. ***P , .001. 6PG, 6-phosphogluconate; 6PGL,
6-phosphogluconolactone; ADP, adenosine 59-diphosphate; ATP, adenosine triphosphate; DHAP, dihydroxyacetone phosphate; E4P, erythrose 4-phosphate; F6P, fructose
6-phosphate; FBP, fructose 1,6-bisphosphate; G6P, glucose 6-phosphate; PRPP, phosphoribosyl pyrophosphate; R5P, ribose 5-phosphate; Ru5P, ribulose 5-phosphate;
S7P, sedoheptulose 7-phosphate; TCA, tricarboxylic acid cycle; Xu5P, xylulose 5-phosphate.
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phosphofructokinase and thereby accelerates one of the rate-
limiting steps in glycolysis (Figure 5E).31 Pfkfb3 can be inhibited
by 3PO,32 a small molecule that was found to reduce the in-
tracellular concentration of F2,6BP and thereby to suppresses
glycolysis.31 We first tested 3PO alone or in combination with
ruxolitinib on growth, survival, and metabolic activity in human
myeloid cell lines SET2, HEL, and UKE1 that express VF and in
K562 cells that are transformed by BCR-ABL. We confirmed that
PFKFB3 was expressed in these cells (supplemental Figure 6A).
Treatment with 3PO alone increased apoptosis and attenu-
ated the proliferation of all VF-expressing cell lines in a dose-
dependent manner, and this effect was additive with ruxolitinib
(Figure 6A-B; supplemental Figure 6B). In contrast, K562 cells
were susceptible to 3PO treatment only at high concentrations
(Figure 6A-B). VF-expressing cell lines treated with 3PO alone for
12 hours showed markedly reduced glycolytic rate in a dose-
dependent manner and exhibited additive effects with rux-
olitinib (Figure 6C). Interestingly, 3PO also reduced mitochon-
drial oxygen consumption rate (Figure 6D), possibly because of
reduced supply of glycolysis pathway intermediates to the TCA
cycle. Under similar conditions, no effect of 3PO on glycolysis or
oxygen consumption was observed in K562 cells. These results
suggest that human cell lines expressing VF highly depend on
glycolysis and are susceptible to apoptotic cell death when
subjected to glycolytic blockade.
Perturbation of glycolysis and mitochondrial respiration can lead
to altered redox homeostasis and aberrant levels of ROS. 3PO
alone caused an increase in total ROS levels at just 6 hours after
treatment (supplemental Figure 6C). Elevated ROS levels in
SET2 cells persisted for at least 24 hours (Figure 6E) and resulted
in increased apoptosis and decreased proliferation (Figure 6F-
G). This suggested that the blockade of glycolysis by 3PO in VF-
expressing cells rapidly depleted cellular antioxidant capacities.
Indeed, treatment with 3PO alone or in combination with
ruxolitinib reduced the GSH/glutathione disulfide (the oxidized
form of GSH) ratio (Figure 6H). Consistent with diminished GSH/
glutathione disulfide ratios, 3PO treatment alone or in combi-
nation with ruxolitinib also substantially reduced NADPH levels
(Figure 6I), suggesting that decreased flux through the pentose
phosphate pathway contributed to exhaustion of reductive re-
serves and defects in redox homeostasis in VF cells. The func-
tional consequences of ROS-mediated actions are highly dose
dependent; moderate increases in ROS may potentiate cell
survival and proliferation, whereas high ROS levels that exceed
cellular antioxidant capacity are detrimental to cell survival.33,34
The depleted antioxidant capacities of GSH or NADPH
could be partially rescued by NAC, a potent ROS scavenger
(Figure 6H-I).33 NAC treatment in SET2 cells not only lowered
ROS levels close to baseline (Figure 6E), but also rescued OCR
(supplemental Figure 6D) as well as the cell survival and pro-
liferation disadvantage caused by 3PO (Figure 6E-H). 3PO
treatment also caused apoptosis of peripheral blood mono-
nuclear cells from MPN patients with high VF allele burden,
which was rescued by NAC pretreatment (supplemental Figure 7).
These data suggest that inhibition of glycolysis through 3PO
increased ROS levels above the cellular antioxidant capacity and
thereby contributed to inhibiting proliferation and survival of
VF-expressing cells.
We then assessed the efficacy and tolerability of 3PO treatment
in vivo in a cohort of VF and E12 mice. To allow monitoring of
mutant JAK2 allele burden, competitive transplantation of BM
coexpressing mutant JAK2 with a GFP reporter in VF and WT
mice in a 1:1 mixture was performed (Figure 7A). Recipient mice
treated with 3PO alone or in combination with ruxolitinib for
8 weeks showed reduction in spleen weight, increase in epi-
didymal white adipose tissue, and improved glucose levels,
including normalization of glucose tolerance (Figure 7B-E). 3PO
also restored body fat in JAK2-mutant mice (supplemental
Figure 8A), and combination with ruxolitinib augmented these
beneficial effects (Figure 7B-E). Consistently, MPN patients
significantly gained body weight when treated with ruxolitinib
(supplemental Figure 8B), in line with previous reports.35,36 In VF
mice, 3PO treatment alone also reduced red cell numbers,
hemoglobin levels, and neutrophils (Figure 7F). These reduc-
tions were accentuated in combination of 3PO with ruxolitinib.
3PO alone had no effect on platelet counts, whereas ruxolitinib
alone or in combination with 3PO increased platelet numbers
in VF and E12 mice. This paradoxical effect of ruxolitinib on
platelets has been reported previously.18,37 Our data obtained in
human hematopoietic cell lines expressing VF and primary
samples from MPN patients suggest that the same metabolic
alterations as in mouse models are present in human MPNs.
Furthermore, PV patients receiving cytoreductive therapies
showed higher glucose levels (95.36 13.5 mg/dL) as compared
with PV patients treated with phlebotomy only (81.86 6.1mg/dL;
Figure 7G). Taken together, these data suggest that targeting
metabolic alterations in MPNs may open new therapeutic op-
portunities for human MPNs as well.
Discussion
We show that expression of mutant JAK2 in mouse models of
MPNs induced profound metabolic alterations that have been
hitherto overlooked, with strongly increased energy demands
and vital dependence on glucose. In mouse models of acute
myeloid leukemia, leukemic cells expressing both BCR/ABL and
NUP98/HOXA9 or MLL-AF9 alone imposed systemic metabolic
changes, resulting inmild hypoglycemia withmarkedly decreased
Figure 6. Dual treatment with 3PO and ruxolitinib induces cell-proliferation arrest and apoptosis in human cell lines expressing VF by altering redox homeostasis. (A)
Apoptosis rate was determined by percentage of annexin V1 cells in indicated human myeloid leukemia cells after treatment with 3PO and/or ruxolitinib for 48 hours (n 5 3
independent experiments). (B) Cell proliferation was determined by percentage of Ki671 cells in indicated human myeloid leukemia cells in the presence of 3PO and/or
ruxolitinib for 48 hours (n5 3 independent experiments). (C) Measurements of extracellular acidification rate (ECAR), indicative of glycolytic rates, in SET2, HEL UKE1, and K562
cells after treatment with 3PO and/or ruxolitinib for 12 to 16 hours (n 5 3 independent experiments). (D) Measurements of OCR, indicative of mitochondrial oxidative
phosphorylation, in indicated cells after treatment with 3PO and/or ruxolitinib for 12 to 16 hours (n5 3 independent experiments). (E) Total reactive oxygen species (ROS) levels
in SET2 cells after treatment with 3PO and/or ruxolitinib for 24 hours. Cells were pretreated with 1.5 mM of N-acetyl-cysteine (NAC) for 6 hours. Data were normalized to vehicle-
treated control (n5 3 independent experiments). (F-G) Apoptosis rate (F) and cell proliferation (G) were determined in SET2 cells treated with 3PO and/or ruxolitinib and/or NAC
for 48 hours. Cells were pretreated with NAC for 6 hours. Normalized values to vehicle-treated controls are shown. (H-I) Ratio of glutathione (GSH)/glutathione disulfide (GSSG)
(H) and NADPH levels (I) in SET2 cells treated with 3PO and/or ruxolitinib for 12 hours. Cells were pretreated with NAC for 6 hours. Normalized values to vehicle-treated controls
are shown. All data are presented as mean6 standard error of the mean. Two-way analyses of variance with subsequent Bonferroni posttests were used. See also supplemental
Figure 7. *P , .05, **P , .01, ***P , .001. MFI, mean fluorescence intensity.
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Figure 7. Combined targeting of elevated glycolysis and mutant JAK2 activity elicited additive effects in vivo. (A) Schematic of long-term 3PO and ruxolitinib treatment.
Competitive BM transplant recipient mice were induced with tamoxifen (TAM) to activate the VF and E12mutations; 4 (for E12) or 8 weeks (for VF) later, the treatment regimen
was initiated. Mice were treated with vehicle or 3PO (50 mg/kg, intraperitoneally) alone or in combination with ruxolitinib (60 mg/kg orally) every day for 8 weeks. (B)
Representative pictures and weights of spleen frommice treated with vehicle or 3PO and/or ruxolitinib (n5 6 mice per genotype). (C) Weight of epididymal white adipose tissue
(eWAT) in 3PO- and/or ruxolitinib-treatedmice (n5 6mice per genotype). (D) Time course of nonfasting blood glucose levels in 3PO- and/or ruxolitinib-treatedmice (n5 6mice
per genotype). (E) Glucose tolerance test in 3PO- and/or ruxolitinib-treated VF (left) and E12mice (right) (n5 6 mice per genotype). (F) Peripheral blood cell counts (upper) and
frequencies of GFP1 hematopoietic cells in peripheral blood (lower) in 3PO- and/or ruxolitinib-treatedmice at indicated time points (n5 6mice per genotype). (G) Blood glucose
levels in PV patients with or without cytoreductive therapy. Cytoreductive drugs were hydroxyurea (n 5 19), pegylated interferon-a (n 5 1), ruxolitinib (n 5 3), and anagrelide
(n5 1). (H) Schematic drawing depicting the metabolic changes in hematopoietic and nonhematopoietic tissues induced by expression of mutant JAK2 in hematopoietic cells.
Metabolic changes and MPNs are primarily driven by the expression of mutant JAK2 in hematopoietic cells. HGD promoted proliferation of the JAK2-mutant clone and
accelerated MPN phenotype, whereas ruxolitinib, 3PO, and HFD reduced the MPN manifestations. Note that some changes in metabolism were direct effects of the JAK2-
mutant hematopoietic cells, whereas other changes (eg, lipolysis) were indirect consequences of the general energy crisis and/or inflammatory mediators secreted by the JAK2-
mutant cells. One-way analyses of variance (ANOVAs) followed by Tukey’s multiple comparison tests were used for multiple-group comparisons, or 2-way ANOVA with
subsequent Bonferroni posttest or 2-tailed unpaired t test (G) was used. All data are presented as mean6 standard error of the mean. See also supplemental Figure 8. *P, .05,
**P , .01. CBC, complete blood count.
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insulin levels and insulin resistance.38 In contrast, our mutant JAK2
models displayed a more profound hypoglycemia without signs
of insulin resistance, implying that acute myeloid leukemia and
MPN cells differ in type and extent of the metabolic reprogram-
ing. Hypoglycemia strongly correlated with degree of increased
erythropoiesis, consistent with the critical role of glucose me-
tabolism in normal erythropoiesis.39 E12mice, with predominantly
erythroid hyperproliferation, had a more severe hypoglycemia
than VFmice, which displayed trilineage involvement and amilder
erythroid phenotype. Hypoglycemia was also observed in Tg6
mice that exhibitedmassive erythrocytosis as a result of transgenic
overexpression of Epo under the control of the human PDGFR
promoter.24,25 This suggests that excessive Epo signaling through
WT JAK2 can lead to metabolic alterations similar to those from
signaling through mutant JAK2.
In addition to altered glucose metabolism, JAK2-mutant mice
also exhibited increased lipid catabolism. The changes in lipid
metabolism could have been a consequence of the general
energy crisis induced by hypoglycemia, but chronic inflamma-
tion mediated by elevated cytokine production may have further
contributed to lipolysis in a non–cell-autonomous way. Cachexia
in advanced primary myelofibrosis has also been linked to increased
levels of proinflammatory cytokines.40 Tg6 mice also showed
decreased fat stores,25 supporting a connection between excess
erythropoiesis and lipolysis. However, Tg6 mice typically survive
for 28 to 32 weeks,41 whereas E12mice die within 8 to 10 weeks.
Thus, signaling through mutant JAK2 has more deleterious con-
sequences than signaling through WT JAK2 because of over-
expressing of Epo.
Metabolic phenotyping and gene expression analyses of
HSPCs revealed profound alterations in multiple metabolic
pathways and allowed us to identify several potentially rate-
limiting steps in glycolysis, pentose phosphate cycle, and citrate
cycle. Inhibiting glycolysis by 3PO in VF-expressing human cell
lines reduced proliferation and increased apoptosis through a
mechanism that involved greatly increased ROS levels (Figure 6).
Although the extent of metabolic alterations in patients with
MPNs remains to be determined, the effectiveness of 3PO in-
hibition in JAK2-mutant human cell lines and primary samples
from MPN patients is encouraging. 3PO also reduced blood
counts and spleen size and normalized glucose levels and fat
tissue in JAK2-mutant mice in vivo, further suggesting that li-
polysis is primarily driven by increased glucose consumption and
energy crisis (Figure 7H). Poor water solubility of 3POmakes this
compound difficult to administer in patients. However, deriva-
tives of 3PO, such as PFK15 and PFK-158, which also inhibit
PFKFB3, are now in clinical trials for treating late-stage cancer
patients.42
Increased glutamine metabolism was reported in BaF/3 cells
expressing VF mutation.43 It will be interesting to determine
whether targeting glutamine metabolism alone or in combina-
tion with inhibition of glycolysis can improve therapy for MPNs.
A recent study investigated the cell-autonomous metabolic
changes in mutant IDH2/JAK2–driven MPNs (present in 2% of
MPN patients) and demonstrated that JAK2/IDH-mutant cells
are sensitive to an IDH2 inhibitor.44 Although the presence of
additional somatic mutations in MPNs may be difficult to target
therapeutically, the resultant metabolic abnormalities might be
common for different driver mutations and could represent new
therapeutic targets.
Our findings support the potential of elucidating additional
MPN cell–specific metabolic properties and provide a rationale
for testing metabolic inhibitors in MPNs using a 2-pronged
approach of cotargeting altered metabolic dependencies and
mutant JAK2 activity.
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